
|Videos|October 18, 2017
Dr. Shah Discusses Autologous Transplant in MCL
Author(s)Bijal D. Shah, MD
Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses autologous stem cell transplant (ASCT) in mantle cell lymphoma (MCL).
Advertisement
Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses autologous stem cell transplant (ASCT) in mantle cell lymphoma (MCL).
Not all patients with MCL in first remission should receive ASCT, says Shah. The main alternative would be rituximab (Rituxan) maintenance therapy, but there is not yet enough information on duration of treatment with this approach.
Shah says, at this point, it is up to the patient to either undergo transplant or rituximab maintenance.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5



































